Ligand completes $739M acquisition of XOMA Royalty Corporation

Ligand (LGND) completed its acquisition of XOMA Royalty for $39.00/share, valuing the equity at ~$739M, adding 7 commercial products and 14 late-stage development programs to expand its royalty portfolio to 200+ assets. The deal is expected to add ~$0.50 and $1.50 per share to 2026 and 2027 adjusted EPS, respectively. Investor reaction appears strong, with shares trading around $309.25 near the 52-week high, and multiple analysts reiterated Buy ratings while raising price targets.

Analysis

This is a balance-sheet and portfolio-construction story more than a pure M&A rerate. LGND is effectively buying long-duration royalty optionality while it still trades like a growth asset, but the market is already capitalizing a lot of the 2026-27 accretion today; that makes the next leg dependent on proof that the acquired stream is not just larger, but cleaner and less clustered than expected. The post-deal setup is therefore less about headline EPS and more about whether financing costs, amortization, and integration complexity stay below the implied contribution from the new portfolio.

The main second-order winner is LGND’s own equity currency: a larger asset base and broader deal-sourcing platform can compress perceived idiosyncratic risk and help the stock retain a premium multiple versus smaller royalty platforms. The losers are the smaller, more concentrated royalty vehicles and single-asset biotech names that now compete for capital against a scaled consolidator with cheaper cost of capital; if LGND continues to use paper and debt to roll up assets, it can pressure valuation multiples across the niche. XOMA is effectively a dead ticker from a trading standpoint, while RHHBY, TAK, and ZVRA are not direct losers operationally, but their embedded royalty streams are now valued inside a bigger basket where headline asset quality matters less than portfolio breadth.

The near-term risk is that investors extrapolate pro forma EPS without fully discounting interest expense from the convert and the fact that royalty cash flows can be lumpy by product, geography, and launch timing. Over 1-3 months, the stock is vulnerable to any disclosure that the acquired assets are concentrated in later-stage or litigation-sensitive cash flows, or that incremental accretion is back-end loaded. Over 6-18 months, the key falsifier is guidance: if management cannot convert the larger portfolio into better cash conversion and still needs more leverage to keep buying, the multiple can compress fast despite the growth narrative.

Key Decisions for Investors

• Do not chase LGND after the close; wait for the first post-close earnings update or 10-Q to verify cash conversion and interest burden before adding. Risk/reward is poor here unless management raises 2026-27 guidance again.
• For existing LGND longs, tighten stops or consider a partial trim into strength; thesis fails if the market stops rewarding portfolio breadth and starts focusing on leverage-adjusted cash EPS.
• Set an alert on LGND if the stock loses the post-deal breakout zone on heavy volume; that would signal the market is discounting integration/financing risk faster than accretion.
• Watch ZVRA and TAK as sentiment beneficiaries only if sell-side starts marking up asset values across externalized royalty portfolios; otherwise, no direct trade is warranted.
• Avoid XOMA follow-through trading; the equity is gone and any residual CVR value is litigation-dependent, making it a contingent event, not an investable operating thesis.